Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Nature. 2021 Feb;590(7846):492-497. doi: 10.1038/s41586-020-03133-3. Epub 2021 Jan 27.
Whole-genome doubling (WGD) is common in human cancers, occurring early in tumorigenesis and generating genetically unstable tetraploid cells that fuel tumour development. Cells that undergo WGD (WGD cells) must adapt to accommodate their abnormal tetraploid state; however, the nature of these adaptations, and whether they confer vulnerabilities that can be exploited therapeutically, is unclear. Here, using sequencing data from roughly 10,000 primary human cancer samples and essentiality data from approximately 600 cancer cell lines, we show that WGD gives rise to common genetic traits that are accompanied by unique vulnerabilities. We reveal that WGD cells are more dependent than WGD cells on signalling from the spindle-assembly checkpoint, DNA-replication factors and proteasome function. We also identify KIF18A, which encodes a mitotic kinesin protein, as being specifically required for the viability of WGD cells. Although KIF18A is largely dispensable for accurate chromosome segregation during mitosis in WGD cells, its loss induces notable mitotic errors in WGD cells, ultimately impairing cell viability. Collectively, our results suggest new strategies for specifically targeting WGD cancer cells while sparing the normal, non-transformed WGD cells that comprise human tissue.
全基因组加倍(WGD)在人类癌症中很常见,它发生在肿瘤发生的早期,产生遗传不稳定的四倍体细胞,为肿瘤的发展提供动力。经历全基因组加倍的细胞(WGD 细胞)必须适应其异常的四倍体状态;然而,这些适应的性质,以及它们是否赋予可以被治疗利用的脆弱性,尚不清楚。在这里,我们使用大约 10000 个人类原发性癌症样本的测序数据和约 600 个癌细胞系的必需性数据,表明 WGD 产生了常见的遗传特征,同时伴随着独特的脆弱性。我们揭示 WGD 细胞比 WGD 细胞更依赖于纺锤体组装检查点、DNA 复制因子和蛋白酶体功能的信号。我们还发现,编码有丝分裂驱动蛋白的 KIF18A 蛋白对于 WGD 细胞的存活是特异性必需的。尽管 KIF18A 在 WGD 细胞中进行有丝分裂时对于准确的染色体分离大多是可有可无的,但它的缺失会在 WGD 细胞中引起明显的有丝分裂错误,最终损害细胞活力。总的来说,我们的研究结果表明了针对 WGD 癌细胞的新策略,同时可以保留构成人体组织的正常、未转化的 WGD 细胞。
Life Sci Alliance. 2024-10
Oncotarget. 2016-1-5
Trends Genet. 2023-12
Int J Mol Sci. 2023-2-13
Genes (Basel). 2025-6-14
Front Med (Lausanne). 2025-5-7
Nat Rev Genet. 2019-9-23
Bioinformatics. 2020-2-15
J Cell Biol. 2018-12-11
Nat Rev Cancer. 2019-1